Overall rank by patents
#5,669
of 50,000 tracked assignees
USPTO PatentsView assignee record - 60 granted patents across 20 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12P (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE).
The verdict
According to USPTO PatentsView, Evolva ranks #5,669 of 50,000 tracked US assignees by granted-patent volume, with 60 patents across 20 technology areas.
USPTO PatentsView assignee plate
Corpus R5669 · Foreign Corporation #5,669 · 60 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL
Nearest grant-volume peer: Dow Technology Investments Llc (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Prothena Biosciences · near
43 score
Evolva · this assignee
43 score
Hiperbaric · near
43 score
Loop Commerce · near
43 score
GE Medical Systems G… · near
43 score
3D Lighting Innovati… · lowest
7 score
What this shows Evolva Sa stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-FOCUS, INNOV-PAR, CLAIMS-RICH, TYPE-FRNCORP, VEL-FLAT, BOOK-FULL. Volume places it #5,669 of 50,000; Innovation Score 43.3/100 sits in the top 29% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Dow Technology Investments Llc (±0 grants).
Evolva Sa has been granted 60 US utility patents between 2015 and 2024, placing Evolva Sa at #5,669 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 20 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.8 claims per patent with primary concentration in C12P (FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE). As a Foreign Corporation, Evolva Sa is one of the more focused assignees in the PatentsView dataset. By volume, Evolva sits between Dow Technology Investments Llc (60 patents, rank #5,663) and Generac Power Systems, Inc. (60 patents, rank #5,671) - the closest US assignees by grant volume. The composite Innovation Score of 43.3/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 30 grants, compared with 30 in the 2015–2019 window, a +0% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Evolva Sa's 18.8 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 20 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Dow Technology Investments LLC
60 patents
Dyaco International Inc.
60 patents
EAST CHINA NORMAL UNIVERSITY
60 patents
EVERICH AND TOMIC HOUSEWARES CO., LTD.
60 patents
Everlast Climbing Industries, Inc.
60 patents
F.S.KOREA INDUSTRIES INC.
60 patents
GUANGDONG MIDEA KITCHEN APPLIANCES MANUFACTURING CO., LTD.
60 patents
Generac Power Systems, Inc.
60 patents
EVOLVA SA
60 patents
What this shows Evolva holds 60 patents at rank #5,667, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #5,667 in granted patent volume.
Other assignees with the most granted patents in Evolva's primary technology class.
Two PlainPatent-derived peer sets for Evolva, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (43 here).
Nearest assignees by average claims per patent (18.8 here).
Evolva's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
43 Top 29% higher than 71% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 5.0% |
| 2016 | 3 | 5.0% |
| 2017 | 7 | 11.7% |
| 2018 | 7 | 11.7% |
| 2019 | 10 | 16.7% |
| 2020 | 10 | 16.7% |
| 2021 | 11 | 18.3% |
| 2022 | 4 | 6.7% |
| 2023 | 4 | 6.7% |
| 2024 | 1 | 1.7% |
Top 15 of 20 technology areas
Overall rank by patents
#5,669
of 50,000 tracked assignees
43.3 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.